search
Back to results

The Role of Calcipotriol as Radioprotector of Skin

Primary Purpose

Radiodermatitis

Status
Unknown status
Phase
Phase 2
Locations
Israel
Study Type
Interventional
Intervention
Calcipotriol
Sponsored by
Rabin Medical Center
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Radiodermatitis focused on measuring Calcipotriol, Breast, Cancer, Radiotherapy, Radiodermatitis in Breast Cancer

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age ranging from 18 to 75.
  2. Confirmed histological diagnosis of Breast cancer.
  3. Radiotherapy treatment to the breast following lumpectomy.

Exclusion Criteria:

  1. Scleroderma.
  2. An extremely large breast. Interfiled above 25 cm.
  3. Prior radiotherapy to the same breast, radiotherapy to the contra lateral breast is not a contraindication.
  4. Mastectomy.

Sites / Locations

  • Rabin Medical Center

Outcomes

Primary Outcome Measures

Prevention of radiodermatitis

Secondary Outcome Measures

Side effects of Calcipotriol

Full Information

First Posted
March 7, 2007
Last Updated
March 7, 2007
Sponsor
Rabin Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT00445250
Brief Title
The Role of Calcipotriol as Radioprotector of Skin
Official Title
Phase 2 Study of the Role of Calcipotriol as Radioprotector of Skin in Women Receiving Radiotherapy Treatment to the Breast.
Study Type
Interventional

2. Study Status

Record Verification Date
January 2007
Overall Recruitment Status
Unknown status
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Rabin Medical Center

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Examining the hypothesis that protecting keratinocytes by calcipotriol can prevent in-vivo cutaneous side effect in patients receiving radiotherapy to the breast. To check the connection between the skin effect of radiotherapy and different parameters including diseases such as diabetes and lupus, use of medications, allergies, weight, habits, size of the irradiated breast, previous chemotherapy treatment and exposure to sunlight.
Detailed Description
STUDY PROTOCOL Fifty women diagnosed with breast cancer planned to receive adjuvant radiotherapy, will participate in the study. About 15 minutes after receiving the daily radiation dose fraction, a cream containing an active vitamin D analogue will be applied to half of the breast with inspection of a nurse. The other half of the breast will have a standard cream applied . During the days that radiotherapy is not administered the standard cream will be applied to both halves of the breast in a case of strong reaction to radiotherapy (e.g. strong erythema, painful tenderness etc.)The adverse skin effects will be assessed according to the following criteria: . an assessment by a physician and a nurse according to the RTOG score (6). As follows: Grade 0 - no reaction. Grade 1 - light erythema dry peeling, decrease in sweat production. Grade 3 - extensive moist peeling, pitting edema. Grade 4 - ulcers, bleeding and necrosis. . A questionnaire to each patient regarding the efficacy and safety of the cream. . Number of interruption of radiotherapy treatment. The assessment will be done each week during radiotherapy treatment and weekly for three weeks following the completion of radiotherapy treatment. Safety report will be sent to the local independent ethics committee after the examination of the first ten patients. The protective effect of the cream containing calcipotriol will be compared to the standard treatment and analyzed statistically using the parameters mention above. The relation between the background disease, medications, allergies, weight, habits, size of the irradiated breast, sun exposure, previous chemotherapy treatment and exposure to sunlight and the skin reaction will be evaluated. INCLUSION CRITERIA . Age ranging from 18 to 75. . Confirmed histological diagnosis of Breast cancer. . Radiotherapy treatment to the breast following lumpectomy. EXCLUSION CRITERIA . Scleroderma. . An extremely large breast. Interfiled above 25 cm. . Prior radiotherapy to the same breast, radiotherapy to the contra lateral breast is not a contraindication. . Mastectomy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Radiodermatitis
Keywords
Calcipotriol, Breast, Cancer, Radiotherapy, Radiodermatitis in Breast Cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
50 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Calcipotriol
Primary Outcome Measure Information:
Title
Prevention of radiodermatitis
Secondary Outcome Measure Information:
Title
Side effects of Calcipotriol

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ranging from 18 to 75. Confirmed histological diagnosis of Breast cancer. Radiotherapy treatment to the breast following lumpectomy. Exclusion Criteria: Scleroderma. An extremely large breast. Interfiled above 25 cm. Prior radiotherapy to the same breast, radiotherapy to the contra lateral breast is not a contraindication. Mastectomy.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Eyal Fenig, M.D.
Phone
97239377964
Email
efenig@clalit.org.il
First Name & Middle Initial & Last Name or Official Title & Degree
Ofer Purim, M.D.
Phone
97239377973
Email
oferp@clalit.org.il
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eyal Fenig, M.D.
Organizational Affiliation
Rabin Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Rabin Medical Center
City
Petach Tiqva
ZIP/Postal Code
49100
Country
Israel
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eyal Fenig, M.D.
Phone
97239377964
Email
efenig@clalit.org.il
First Name & Middle Initial & Last Name & Degree
Ofer Purim, M.D.
Phone
97239377973
Email
oferp@clalit.org.il
First Name & Middle Initial & Last Name & Degree
Eyal Fenig, M.D.
First Name & Middle Initial & Last Name & Degree
Ofer Purim, M.D.
First Name & Middle Initial & Last Name & Degree
Amir Abramovich, M.D.

12. IPD Sharing Statement

Learn more about this trial

The Role of Calcipotriol as Radioprotector of Skin

We'll reach out to this number within 24 hrs